Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Add to my list  
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
07/17/2018 07/18/2018 07/19/2018 07/20/2018 07/23/2018 Date
16.145(c) 16.38(c) 16.685(c) 17.42(c) 17.45 Last
735 116 854 557 848 053 2 072 724 247 132 Volume
-0.03% +1.46% +1.86% +4.41% +0.17% Change
More quotes
Financials (EUR)
Sales 2018 353 M
EBIT 2018 48,4 M
Net income 2018 34,2 M
Debt 2018 70,3 M
Yield 2018 -
Sales 2019 379 M
EBIT 2019 58,9 M
Net income 2019 48,0 M
Debt 2019 32,5 M
Yield 2019 -
P/E ratio 2018 74,13
P/E ratio 2019 52,16
EV / Sales2018 7,48x
EV / Sales2019 6,87x
Capitalization 2 570 M
More Financials
Company
Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies.It operates through the EVT Execute and EVT Innovate segments.The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes... 
More about the company
Surperformance© ratings of Evotec AG
Trading Rating : Investor Rating :
More Ratings
Latest news on EVOTEC AG
07/19EVOTEC AG : Evotec Receives Milestone Payment For Start Of Phase II Trial In Its..
AC
07/19EVOTEC : Receives milestone payment for start of phase ii trial in its multi-tar..
EQ
07/09EVOTEC : confirm closing of transaction with Sanofi to accelerate infectious dis..
AQ
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
07/03EVOTEC AG : Evotec Confirm Closing Of Transaction With Sanofi To Accelerate Infe..
AC
07/03EVOTEC : Confirm closing of transaction with sanofi to accelerate infectious dis..
EQ
06/28EVOTEC : achieves second milestone in diabetes alliance with Sanofi
AQ
06/25EVOTEC AG : Evotec Achieves Second Milestone in Diabetes Alliance With Sanofi
AC
06/25EVOTEC : Resolutions of the Annual General Meeting 2018 of Evotec AG
AQ
06/25EVOTEC : Achieves second milestone in diabetes alliance with sanofi
EQ
More news
Sector news : Biotechnology & Medical Research - NEC
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on EVOTEC AG 
EVOTEC AG - 2017
A good level to buy
BUY
More Strategies
Latest Tweets
07/19EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF PHASE II TRIAL IN ITS MULTI-TA..
1
07/03EVOTEC CONFIRM CLOSING OF TRANSACTION WITH SANOFI TO ACCELERATE INFECTIOUS DI..
1
07/01Nordex, Evotec, Netflix – unsere Investmentideen  
06/25EVOTEC ACHIEVES SECOND MILESTONE IN DIABETES ALLIANCE WITH SANOFI
1
06/20RESOLUTIONS OF THE ANNUAL GENERAL MEETING 2018 OF EVOTEC AG  
More tweets
Qtime:51
News from SeekingAlpha
05/31Evotec forms LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research .. 
05/21Celgene teams up with Evotec to discover new cancer treatments 
05/09Evotec's (EVOTF) CEO Werner Lanthaler on Q1 2018 Results - Earnings Call Tran.. 
05/09Evotec AG 2018 Q1 - Results - Earnings Call Slides 
05/09Evotec AG reports Q1 results 
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 19,9 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG29.04%2 885
CELLTRION, INC.--.--%32 245
IQVIA HOLDINGS INC13.49%22 746
LONZA GROUP8.32%21 355
INCYTE CORPORATION-26.93%14 861
SEATTLE GENETICS, INC.31.33%11 158